Apply to trial NCT07587515

A few quick questions so the study team can decide if you might be a fit.

RecruitingBiological intervention

Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening